ArticleCancer research and treatment2016
A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting.
Article in Cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain.PloS one · 2021Trial
- Development and preliminary validation of a clinician-administered Chinese-language tool for breakthrough cancer pain assessment.Asia-Pacific journal of oncology nursing · 2026Article
- A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients.Cancer research and treatment · 2025Observational
- Article
- Breakthrough pain among cancer patients at oncology units in Northern Ethiopia; a multi-center study.Frontiers in oncology · 2023Article
- Article
- High-rate breakthrough cancer pain and tumour characteristics - literature review and case series.Drugs in context · 2023Review
- Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits.Drugs in context · 2023Review
- Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment - case series and review of the literature.Drugs in context · 2022Review
- Interference with daily functioning by breakthrough pain in patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.The Korean journal of internal medicine · 2018Article
- Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the prevalence and characteristics of breakthrough cancer pain (BTcP) in Korean patients admitted with cancer pain. MATERIALS AND
methodsIn-hospital patients with cancer pain completed a questionnaire concerning severity of background cancer pain (BCP), prevalence and treatment for BTcP, sleep disorders, and satisfaction with cancer pain treatment. Medical records showing medications for BCP and BTcP were also evaluated.
resultsTotal 609 patients with controlled BCP enrolled. Mean age of the patients was 59.5 years old, and 59% were male. Of all patients, 177 (29%) complained of BTcP. No clinical characteristic predicted BTcP. Of the 177 patients with BTcP, 56% did not receive treatment for BTcP. Patients with BTcP showed significant association with a sleep disorder and dissatisfaction with pain control, compared to those without BTcP (p < 0.0001 and p=0.0498, respectively). Oxycodone-immediate release was the most commonly used short-acting analgesic, followed by intravenous morphine.
conclusionThe prevalence of BTcP was 29% in patients admitted with controlled BCP. Although the patients had well-controlled BCP, BTcP showed association with a lower quality of life in patients with cancer. More medical attention is needed for detection and management of BTcP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.